Florence I. Raynaud

Regulation and targeting of the hypoxia-inducible pathway

Va Carroll, Noan-Minh Chau, Nicola E. Wilsher, 2005 .

Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)

Isaac M. Westwood, Julian Blagg, Florence I. Raynaud, 2013, Journal of medicinal chemistry.

The pharmacological audit trail (PhAT): Use of tumor models to address critical issues in the preclinical development of targeted anticancer drugs

Paul Workman, Florence I. Raynaud, Suzanne A. Eccles, 2016 .

Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

Gary Box, Ian Collins, Isaac M. Westwood, 2011, Journal of medicinal chemistry.

Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease

Florence I. Raynaud, Kevin Petrie, William A. Weiss, 2015, Cancer cell.

Effect of sleep deprivation on the human metabolome

Florence I. Raynaud, Alfred E. Thumser, Benita Middleton, 2014, Proceedings of the National Academy of Sciences.

Optimization of imidazo [4, 5-b] pyridine-based kinase inhibitors: identification of a dual FLT3/aur

Gary Box, Nathan Brown, Julian Blagg, 2012 .

The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery

Paul Workman, Florence I. Raynaud, P. Workman, 2007, Molecular Cancer Therapeutics.

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

Julian Blagg, Paul Workman, Florence I. Raynaud, 2016, Journal of medicinal chemistry.